JP2022511366A - 神経変性疾患の処置における神経保護剤としてのドネコプリド - Google Patents

神経変性疾患の処置における神経保護剤としてのドネコプリド Download PDF

Info

Publication number
JP2022511366A
JP2022511366A JP2021517453A JP2021517453A JP2022511366A JP 2022511366 A JP2022511366 A JP 2022511366A JP 2021517453 A JP2021517453 A JP 2021517453A JP 2021517453 A JP2021517453 A JP 2021517453A JP 2022511366 A JP2022511366 A JP 2022511366A
Authority
JP
Japan
Prior art keywords
compound
group
mice
neurons
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021517453A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020065028A5 (https=
JP2022511366A5 (https=
Inventor
パトリック・ダルマーニュ
クリストフ・ロシェ
シルヴィ・クレイセン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Caen Normandie
Original Assignee
Universite de Caen Normandie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Caen Normandie filed Critical Universite de Caen Normandie
Publication of JP2022511366A publication Critical patent/JP2022511366A/ja
Publication of JPWO2020065028A5 publication Critical patent/JPWO2020065028A5/ja
Publication of JP2022511366A5 publication Critical patent/JP2022511366A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021517453A 2018-09-28 2019-09-27 神経変性疾患の処置における神経保護剤としてのドネコプリド Pending JP2022511366A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306280.1 2018-09-28
EP18306280.1A EP3628660A1 (en) 2018-09-28 2018-09-28 Donecopride and flucopride as neuroprotective agents in the treatment of neurodegenerative diseases
PCT/EP2019/076229 WO2020065028A1 (en) 2018-09-28 2019-09-27 Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases

Publications (3)

Publication Number Publication Date
JP2022511366A true JP2022511366A (ja) 2022-01-31
JPWO2020065028A5 JPWO2020065028A5 (https=) 2022-10-05
JP2022511366A5 JP2022511366A5 (https=) 2022-10-05

Family

ID=63798921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021517453A Pending JP2022511366A (ja) 2018-09-28 2019-09-27 神経変性疾患の処置における神経保護剤としてのドネコプリド

Country Status (10)

Country Link
US (1) US20220031680A1 (https=)
EP (2) EP3628660A1 (https=)
JP (1) JP2022511366A (https=)
KR (1) KR20210098429A (https=)
CN (1) CN113195452A (https=)
AU (1) AU2019346024B2 (https=)
BR (1) BR112021005952A2 (https=)
CA (1) CA3115342A1 (https=)
SG (1) SG11202103070VA (https=)
WO (1) WO2020065028A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3166060A1 (fr) 2024-09-12 2026-03-13 Université De Caen Normandie Composition pharmaceutique formulée pour être administrée par voie intranasale et utilisable pour le traitement d’une maladie neurodégénérative
FR3166146A1 (fr) 2024-09-12 2026-03-13 Université De Caen Normandie Sel de fumarate de 1-(4-amino-5-chloro-2-méthoxyphényl)-3-[1-(cycloheptylméthyl)-4-pipéridinyl]propan-1-one –Composition pharmaceutique et utilisation associées

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016522215A (ja) * 2013-06-05 2016-07-28 ユニベルシテ ドゥ カーン ノルマンディ プロムネシア効果を有するアセチルコリンエステラーゼ抑制化合物と５ｈｔ４セロトニン作動性受容体作動薬の調製方法並びにその構成薬剤組成
JP2016540796A (ja) * 2013-12-16 2016-12-28 スヴェン・ライフ・サイエンシズ・リミテッド ５−ｈｔ４受容体アゴニストとしてのインダゾール化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
FR2904113A1 (fr) 2006-07-21 2008-01-25 Exonhit Therapeutics S A Sa Procedes et outils pour la therapie de pathologies neurodegeneratives
CN102355902A (zh) * 2009-01-24 2012-02-15 植物药物公共有限公司 神经营养因子介导的病症的处理

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016522215A (ja) * 2013-06-05 2016-07-28 ユニベルシテ ドゥ カーン ノルマンディ プロムネシア効果を有するアセチルコリンエステラーゼ抑制化合物と５ｈｔ４セロトニン作動性受容体作動薬の調製方法並びにその構成薬剤組成
JP2016540796A (ja) * 2013-12-16 2016-12-28 スヴェン・ライフ・サイエンシズ・リミテッド ５−ｈｔ４受容体アゴニストとしてのインダゾール化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CEDRIC LECOUTEY ET AL., PNAS PLUS, JPN6023027948, 2014, pages 3825 - 3830, ISSN: 0005279367 *
CHRISTOPHE ROCHAIS ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, JPN6023027949, 2015, pages 3172 - 3187, ISSN: 0005279368 *
福井 俊哉: "アルツハイマー病治療の今昔物語", 認知神経科学, vol. 13, no. 1, JPN6024009537, 2011, pages 110 - 117, ISSN: 0005279369 *

Also Published As

Publication number Publication date
WO2020065028A1 (en) 2020-04-02
AU2019346024B2 (en) 2024-07-18
EP3628660A1 (en) 2020-04-01
AU2019346024A1 (en) 2021-04-29
SG11202103070VA (en) 2021-04-29
CA3115342A1 (en) 2020-04-02
BR112021005952A2 (pt) 2021-06-29
KR20210098429A (ko) 2021-08-10
US20220031680A1 (en) 2022-02-03
CN113195452A (zh) 2021-07-30
EP3856716A1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
Dixit et al. Vitamin C deficiency in the brain impairs cognition, increases amyloid accumulation and deposition, and oxidative stress in APP/PSEN1 and normally aging mice
Urano et al. Icariin improves memory impairment in Alzheimer's disease model mice (5xFAD) and attenuates amyloid β‐induced neurite atrophy
Inestrosa et al. Nicotine prevents synaptic impairment induced by amyloid-β oligomers through α7-nicotinic acetylcholine receptor activation
JP5712207B2 (ja) 脳疾患及び状態の予防及び治療のための組成物及び方法
Bailey et al. A novel effect of rivastigmine on pre‐synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer’s disease
Easton et al. Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer’s disease
Yu et al. Baicalin attenuates amyloid β oligomers induced memory deficits and mitochondria fragmentation through regulation of PDE-PKA-Drp1 signalling
Kelliny et al. A new approach to model sporadic Alzheimer’s disease by intracerebroventricular streptozotocin injection in APP/PS1 mice
Ma et al. MG53 protects hUC-MSCs against inflammatory damage and synergistically enhances their efficacy in neuroinflammation injured brain through inhibiting NLRP3/caspase-1/IL-1β Axis
JP5968878B2 (ja) イソアクテオシドまたはその製薬上許容される塩の使用
Leung et al. Microglia activation mediates fibrillar amyloid-β toxicity in the aged primate cortex
Wang et al. Mitochondrial localization of SARM1 in acrylamide intoxication induces mitophagy and limits neuropathy
Ju et al. 9R, the cholinesterase and amyloid beta aggregation dual inhibitor, as a multifunctional agent to improve cognitive deficit and neuropathology in the triple-transgenic Alzheimer's disease mouse model
JP2022511366A (ja) 神経変性疾患の処置における神経保護剤としてのドネコプリド
KR20210098428A (ko) 신경퇴행성 질환의 치료에서 신경보호제로서 아세틸콜린에스테라제 억제제 및 5-ht4 수용체 작용제의 조합물
RU2800802C2 (ru) Донекоприд как нейропротекторный агент при лечении нейродегенеративных заболеваний
Jiao et al. Anisomycin alleviates cognitive impairments and pathological features in 3xTg-AD mice
Yaghoubi The Effects of Aerobic Training and Omega-3 Intake on Aβ42, Neprilysin, and γ-Secretase in the Hippocampus of Male Rats Alzheimer’s model
Lin et al. Neuroprotective effects of a Multi-Herbal extract on axonal and synaptic disruption in vitro and cognitive impairment in vivo
CN115919822A (zh) 泛硫乙胺在治疗阿尔茨海默病中的应用
CN119055674B (zh) 一种可改善认知的组合物及其在阿尔茨海默病防治中的应用
Liu et al. Blockage of IL-17 ameliorates Aβ-induced neurotoxicity and cognitive decline
KR102612229B1 (ko) N-[(4'-브로모[1,1'-바이페닐]-4-일)설포닐]-l-발린 또는 이의 약제학적으로 허용 가능한 염을 포함하는 아밀로이드 베타의 올리고머화 및 피브릴화 억제용 조성물
RU2676100C1 (ru) Применение производных пиперазина для лечения болезни Альцгеймера и деменций альцгеймеровского типа с нарушенной внутриклеточной кальциевой сигнализацией
Wang et al. Mitophagy eliminates the accumulation of SARM1 on the mitochondria, alleviating programmed axon death in acrylamide neuropathy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240311